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A b s t r a c t 
Sepsis is one of the ten leading causes of death in developed and developing countries. In the United States, sepsis mortality 
approaches that of acute myocardial infarction and exceeds deaths from stroke. Neonates and the elderly are the most vulner-
able patients, with these groups suffering from the highest sepsis mortality. In both groups, many survivors respectively display 
serious developmental disabilities and cognitive decline. The National Institute of Health/National Heart, Lung, and Blood 
Institute Panel redefined sepsis as a “severe endothelial dysfunction syndrome in response to intravascular and extravascular 
infections causing reversible or irreversible injury to the microcirculation responsible for multiple organ failure.” Microvas-
cular endothelial injury in sepsis due to microbial inflammation encompasses small blood vessels (< 100 μm in diameter). 
While the lungs remain the principal organ of interest due to sepsis-associated acute respiratory distress syndrome, “septic 
heart” or “septic cardiomyopathy” accelerates sepsis’ transition to potentially lethal septic shock. This review analyses both 
new advances in understanding the septic mechanism and possible resolutions of sepsis. The concept of a “genomic storm,” 
caused by microbes triggering florid production of inflammatory mediators, is based on septic reprogramming of the human 
genome. This genomic storm leads to microvascular endothelial injury, persistent hypotension, and organ failure. While very 
early control of sepsis-causing bacterial, fungal and viral infections remains crucial for the treatment of sepsis, supportive 
measures are likewise necessary to maintain blood pressure, respiration, and kidney function. New evidence indicates that 
preadmission b-blockers may reduce sepsis-associated mortality. The fundamental role of nuclear signalling in the progres-
sion and resolution of sepsis was established with a new class of cell-penetrating nuclear transport modifiers (NTMs). NTMs 
target the translocation of proinflammatory and metabolic transcription factors to the cell’s nucleus while also enhancing 
bacterial clearance in experimental polymicrobial sepsis models. The result is a 700-fold reduction in the bacterial burden of 
the lungs and improvement of sepsis-associated thrombocytopaenia and blood markers of endothelial injury. When added to 
anti-microbial therapy, NTM has increased survival from 30% to 55%, when compared to antimicrobial therapy alone. Yet, the 
prevention of sepsis remains the most rational and beneficial path. Anti-pneumococcal vaccination has reduced the incidence 
of pneumonia and sepsis caused by increasingly antibiotic-resistant Streptococcus pneumoniae in all age groups. Similarly, the 
incidence of meningococcal sepsis known as “purpura fulminans” has been reduced by a recently approved vaccine thereby 
preventing hearing loss, neurologic damage, and limb amputations in young survivors of septic outbreaks. We urgently need 
further preventive, diagnostic, and therapeutic measures as the tide of sepsis rises in the United States and around the world. 
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REVIEW
“Sometimes the heart sees what is invisible to the eye” 
[H. Jackson Brown, Jr]
INTRODUCTION 
The problem of sepsis, that relentless end-stage of many 
microbial diseases, has been close to my heart and mind for 
many years. I am personally motivated to find a remedy for 
this scourge of modern intensive care units. Therefore, I par-
ticipated in the Working Group on Blood Systems Response 
to Sepsis convened in 2010 by the National Institute of 
Health/National Heart, Lung, and Blood Institute. Our group 
redefined sepsis as a severe endothelial dysfunction syndrome 
in response to intravascular and extravascular infections 
leading to reversible or irreversible injury to microcirculation 
responsible for multiple organ failure [1, 2]. The previous defi-
nition of sepsis, proposed by others in 1992, was a “systemic 
inflammatory response syndrome” (SIRS) [3]. This definition, 
popularly described as a “cytokine storm” was frequently 
criticised as inadequate. “Systemic inflammatory response” is 
the mechanism of many acute and chronic diseases caused by 
autoimmune, metabolic, or physical insults (e.g. trauma and 
burns). Usually, these conditions do not exhibit the potentially 
lethal hypotension characteristic of septic shock [4]. The SIRS 
definition of sepsis was redefined in 2016 as “a life-threatening 
organ dysfunction caused by dysregulated host response to 
infection” [5]. While improved, this definition still does not 
address the fundamental mechanism of organ dysfunction: the 
impairment or collapse of microcirculation [4]. Septic shock, 
a form of microcirculatory failure, is defined by the presence 
of tissue hypoperfusion despite normalisation of systemic 
and regional blood flow [6]. Persistent tissue hypoperfusion 
underlies the failure of multiple organs, including the heart [7]. 
This review focuses on the advances in understanding 
the mechanism of sepsis affecting several key organs. It also 
discusses the genomic storm’s role in sepsis development along 
with new experimental approaches seeking to protect small 
blood vessels damaged directly or indirectly by sepsis-causing 
microbial agents. Informative reviews focused on heart injury 
and dysfunction in sepsis provide an instructive analysis of 
heart-based changes in sepsis [7–10]. Other advances, includ-
ing the potential benefit of preadmission b-blockers in reducing 
sepsis mortality are shedding a new light on the role of adrener-
gic system in sepsis [11], while the analysis of metabolic systems 
strives to stratify sepsis survivors from non-survivors [12, 13]. 
Here, we will focus on the mechanism of microvascular 
endothelial injury in multiple organs, including the heart, and 
experimental cytoprotective measures that increase survival 
and attenuate organ injury due to microbial and metabolic 
inflammation. 
GROUND ZERO OF SEPSIS: MICROCIRCULATION 
COMPRISED OF SMALL BLOOD VESSELS 
A continuous layer of endothelial cells lines precapillary arte-
rioles, capillaries, and postcapillary venules. These endothelial 
cells represent the main interface for blood-tissue exchange 
in heart, lung, brain, liver, kidneys and other organs. The mi-
crovascular endothelium constitutes the largest surface area 
of human circulation grossly exceeding that of macrovessels 
(arteries and veins) (Fig. 1) [14]. As illustrated in this figure, the 
heart and vascular system are interwoven. As a major organ, 
the heart is dependent on microcirculation in which capillary 
endothelial cell and cardiomyocyte form a cardiomyovascular 
unit responsible for homeostatic regulation of heart muscle. 
The endothelium provides anticoagulant shield, regulates 
blood flow, tissue perfusion and oxygenation, blood pressure, 
and tissue temperature. Microbial agents causing lesions in 
small blood vessels in an infected organ, such as the lungs in 
pneumonia, can rapidly compromise the endothelial function 
of other organs including heart (e.g. during pneumococcal sep-
sis). Importantly, endothelial cells in capillaries display a striking 
heterogeneity depending on the organ in which they are em-
bedded [15]. The endothelium can be continuous, discontinu-
ous, fenestrated, or sinusoidal in different organs. For example, 
small blood vessel endothelium is continuous in muscles and 
brain whereas endothelium in kidney glomeruli is fenestrated, 
while in the spleen sinusoids endothelium is discontinuous and 
porous [15]. Thus, the architecture and function of regional 
endothelium that comprises the cardiomyovascular unit in the 
heart differs from that of the neurovascular unit that comprises 
blood-brain barrier. From this perspective, more studies on the 
microcirculation in the heart (see Fig. 2, Coronary Circulation) 
are needed to discern its structural and functional features [16]. 
Moreover, organ-specific microvascular endothelial architec-
ture demands caution in interpreting the microvideoscopic 
analysis of microcirculatory blood flow measured only in 
sublingual mucosa of patients with sepsis [17, 18]. 
During sepsis-causing infections that originate in different 
organs, the small vessel endothelial injury causes hypotension 
and myocardial dysfunction, microvascular leak, acute respira-
tory distress syndrome (ARDS), acute kidney injury (AKI), acute 
brain injury, and thrombocytopenia with or without dissemi-
nated intravascular coagulation (DIC). Importantly, endothelial 
microvascular injury and dysfunction caused by microbial 
agent-induced genomic storm (see below) constitutes the 
common denominator for septic multi-organ failure [19–22]. 
PERSISTENT HYPOTENSION  
(VASOPLEGIA) IN SEPSIS 
Hypotension is a hallmark of sepsis. Hypotension requires 
vigorous resuscitation measures and rapid administration of 
empiric antimicrobial therapy until the infectious agent is 
identified [23, 24]. The vascular tone (resistance) is regulated 
to match blood flow to metabolic demand in order to provide 
adequate perfusion to tissues under different physiological 
conditions [15]. However, sepsis dysregulates this homeostatic 
mechanism. The consequent, persistent hypotension, unre-




lethal outcomes in sepsis [10]. Septic shock is viewed as a bi-
phasic disorder with an early hyperdynamic phase with a high 
cardiac output, low systemic vascular resistance, warm extre- 
mities (‘warm hypotension”) followed by a late, hypodynamic 
Figure 1. A global view of circulation. Arterial circulation is on the left and venous on the right. Microcirculation comprises the 
greatest endothelial surface area (left axis of the upper panel), as represented by the central solid peak. The upper panel right 
axis represents wall shear rate [s–1] with the curve reaching its highest values on the arterial side of microcirculation (precapillary 
arterioles). The lower panel comprises the velocity of blood flow, and indicates that the slowest values correlate with postcapillary 
venules, the terrain of white blood cells emigration (adapted from [14])
Figure 2. Micro-computed tomography imaging and segmentation of coronary vasculature. A. Maximum intensity projection of 
whole rat heart imaged at 21 μm isotropic voxel dimension; B. Apical portion rescanned at 4 μm (images courtesy of Prof. Erik 







phase with low cardiac output and poor perfusion [7]. In this 
setting, hypotension reflects endothelial instability and the 
dysregulated response to catecholamines [25]. Moreover, the 
increased production of nitric oxide (NO) by endothelial NO 
synthase (eNOS) and inducible NO synthase (iNOS), together 
with the generation of prostacyclin by cyclooxygenase (COX)-2, 
mainly contributes to hypotension in sepsis. However, NOS 
inhibitors were variably effective in improving sepsis-induced 
hypotension [26]. Alternatively, the downregulation of vaso-
constrictive receptors activated by angiotensin II, catechola-
mines, and vasopressin may contribute to hypotension [10]. 
LEAKY MICROCIRCULATION IN SEPSIS 
The blood-tissue barrier comprised of microvascular endo-
thelial cells is maintained by intercellular junctions, a com-
plex network of adhesive proteins organised into adherence 
junctions and tight junctions [27]. These “flood gates” to the 
parenchyma of different organs can be opened by a variety 
of microbial and host-produced factors that disrupt micro-
vascular endothelial barrier and produce leaky small blood 
vessels. Microbial virulence factors include Gram-negative 
bacteria lipopolysaccharide (LPS), also known as endotoxin 
[20], staphylococcal alpha toxin [28], or Ebola virus glycopro-
tein [29] among others, that produce gaps in tight junctions 
and adherence junctions allowing the escape of blood plasma. 
The ensuing oedema is one of the five cardinal signs of inflam-
mation [30]. Host-produced inducers of leaky small blood 
vessels include interleukin (IL)-2 [27], pleiotropic cytokine 
IL-6, chemokine monocyte chemotactic protein 1 (MCP-1) 
[31] and vascular endothelial growth factor (VEGF), known 
as “vascular permeability factor” [32, 33]. They uncouple the 
VE-cadherin-p120 catenin complex in adherence junction. In 
contrast, a physiologic blood protein, Slit, stabilises intercel-
lular junctions through binding to endothelial Robo receptor 4 
[21]. Remarkably, the recombinant Slit protein increased 
survival in polymicrobial sepsis while cytokines remained 
elevated. Targeting nuclear transport of stress-responsive 
transcription factors (nuclear factor-kB [NF-kB], activator 
protein 1 [AP-1], nuclear factor of activated T-cells [NFAT], 
and signal transducer and activator of transcription 1 [STAT1]; 
see below) with a cell-penetrating nuclear transport modifier 
(NTM), cSN50 peptide, reduced leaky lung endothelial barrier 
disrupted by the superantigen, staphylococcal enterotoxin B 
[34]. Alternatively, selective targeting of transcription factor 
NF-kB in endothelial cells prevented microvascular leak 
induced by endotoxic LPS or associated with experimental 
polymicrobial sepsis. These countermeasures illustrate the 
importance of cytoprotection of failing microcirculation in 
an experimental sepsis control [20, 21]. 
BIOMARKERS OF ENDOTHELIAL  
INJURY IN SEPSIS 
Biomarkers produced by sepsis-activated and injured endo-
thelium during sepsis can inform about its dysfunction [35]. 
Among them, endothelial cell-produced cell adhesion 
molecules comprise E- and P-selectins. E-selectin is expressed 
due to genomic upregulation evoked by LPS, the primary 
virulence factor of Gram-negative bacteria, and by cytokines, 
such as tumour necrosis factor-a (TNF-a). E-selectin is then 
released into the bloodstream [36, 37]. P-selectin is expressed 
by activated platelets and endothelial cells. P-selectin mediates 
platelet — leukocyte and platelet — endothelial cell interac-
tions while contributing to thrombi formation [38]. Selectins 
can be measured in plasma (rather than in serum to protect 
them from proteolysis during blood clotting and retention in 
the blood clot) of patients with sepsis and in experimental 
animals [39]. 
THROMBOCYTOPENIA AND DISSEMINATED  
INTRAVASCULAR COAGULATION IN SEPSIS 
Circulating blood platelets are surveyors of endothelial integ-
rity [40]. They respond to any break in the continuity of en-
dothelial layer. A decrease in platelet count below 150,000/mL 
has long been recognised as a hallmark of Gram-negative 
bacteremia and ensuing sepsis [41]. Thrombocytopenia in 
sepsis is due to trapping of circulating platelets in zones of en-
dothelial injury [42]. Platelets are also susceptible to cytolytic 
microbial toxins or the membrane attack complex of comple-
ment activated by microbial agents [43]. Heparin is known 
for inducing of anti-platelet factor 4 antibodies, a hallmark of 
heparin-induced thrombocytopenia. Moreover, anti-microbial 
therapy may elicit drug-induced thrombocytopenia [44]. In 
a retrospective study of 304 patients (mean age 68.8 ± 15.8) 
with severe sepsis or septic shock, 47.6% developed throm-
bocytopenia, which was drug-induced in 17.9% of patients 
[44]. Significantly, thrombocytopenic patients suffered more 
episodes of bleeding and were more prone to AKI and ARDS, 
thereby implying protective role of platelets in repairing breaks 
in the microvascular endothelium. These patients had elevated 
serum lactic acid and prolonged requirement for vasopressors 
suggesting more severe microvascular endothelial dysfunction. 
Thrombocytopenia in sepsis may be associated with DIC. 
This form of microvascular thrombosis evolves in reaction to 
a rapid and widespread microbial injury to microvascular en-
dothelium. DIC was observed in 37% of a subset of 145 patients 
with thrombocytopenia as a complication of severe sepsis and 
septic shock diagnosed in a larger cohort of 304 patients [44]. 
The importance of prolonged prothrombin time and throm-
bocytopenia in predicting disease severity and survival was 
stressed in a study of 40 patients with severe sepsis or septic 
shock who were scored for DIC using the International Society 
on Thrombosis and Haemostasis diagnostic criteria; 95% had 
fibrin-related markers (fibrin monomer and D-dimer) [45]. 
Injury to endothelium directly activates the coagulation 
cascade through assembly of a prothrombinase complex 
linked to phosphatidyl serine exposed on injured endothelial 
cell membrane [46]. This mechanism of thrombin formation 




pathway that was unsuccessfully targeted in clinical sepsis 
trials [26]. 
Thrombin generated on the surface of injured endothe-
lium is required for activation of physiologic anticoagulant 
mechanism represented by the thrombomodulin-protein C 
axis [47]. Unexpectedly, a supra-normal dose of protein C 
zymogen concentrate had no significant effect on LPS-induced 
biomarkers of coagulation, fibrinolysis, and inflammation 
while significant protein C activation and production of 
TNF-a were detected in human volunteers [48]. 
There is a continuing uncertainty about heparin therapy 
in DIC. A well-designed prospective study is needed, es-
pecially with different molecular forms of heparin. Early IV 
administration of unfractionated heparin was associated with 
a 12% relative risk reduction in mortality in a retrospective 
propensity-matched cohort study [49]. Similarly, clinical trials 
of antithrombin and thrombomodulin were ineffective [26]. 
Thrombin interacts with PAR1 expressed on micro-
vascular endothelial cells triggering the signalling pathway 
to the nucleus that culminates in nuclear transport of 
stress-responsive transcription factors (SRTFs), NF-kB and 
AP-1, and a loss of barrier function [50]. These SRTFs me-
diate the production of barrier-disrupting cytokine IL-6 and 
chemokine MCP-1 [31, 51]. 
MICROVASCULAR INJURY IN THE HEART  
DURING SEPSIS: “SEPTIC HEART”  
AND “SEPTIC CARDIOMYOPATHY” 
Septic cardiomyopathy has been known for at least 40 years, 
being recognised in 44% patients with sepsis whose likelihood 
of the fatal outcome is raised two to three times [7]. 
The autopsy study of the hearts in sepsis non-survivors, 
with a mean age of 59 years and who spent on average 
24 days in the intensive care units, revealed loss of distinct 
cross-striations and lysis of myofilaments in longitudinal sec-
tions of myocardium. Lipofuscin granules indicated oxidative 
stress. Significant mononuclear cell infiltrates (macrophages?) 
in the interstitium were prominently displayed including the 
expression of TNF-a, which was also detected in cardio-
myocytes, vascular smooth muscles, and endothelial cells as 
compared to control hearts (obtained from accident victims 
without chest injury) [9]. Some of these features of the septic 
heart were replicated in experimental polymicrobial sepsis 
model based on cecal ligation and puncture. In this model, 
dystrophin-glycoprotein complex was disrupted thereby im-
pairing contractile force transmission, a sign of the mechanical 
dysfunction during cardiomyopathies. The loss of this com-
plex reduces the mechanical integrity of the cardiac muscle 
rendering it more susceptible to inflammatory insults [9]. 
As individual cardiomyocytes are connected by cell–cell 
junctions located in intercalated discs, these intercellular 
communication channels are also altered in experimental 
model of polymicrobial sepsis. This contributed to the reduc-
tion of mean ejection fraction, fractional shortening, cardiac 
output, and heart rate. Such abnormalities are also linked to 
intracellular calcium overload counteracted in part by the 
calcium blockers, dandrolene or verapamil [9, 52, 53]. In 
another experimental model of polymicrobial sepsis with fluid 
resuscitation, 527 gene transcripts representing inflammatory 
and cell cycle pathways were significantly upregulated or 
downregulated in septic heart. This genomic reprograming 
was accompanied by mitochondrial swelling and myocardial 
depression [54]. 
In the realm of clinical sepsis, magnetic resonance stud-
ies of the heart suggested reversible myocardial oedema or 
an altered metabolic state, clearly distinct from ischaemia 
and necrosis. Also, a reversible Takotsubo cardiomyopathy 
(broken heart syndrome) pattern has been reported in pa-
tients with sepsis. Finally, Ehrman et al. [7] concluded that 
echocardiographic measures of left (systolic or diastolic) 
and right ventricular function cannot provide reliable prog-
nostic information in patients with sepsis. Similarly, they 
questioned the utility of natriuretic peptide and troponin 
measurements. 
MICROVASCULAR ENDOTHELIUM IS UNDER  
THE SIEGE BY SEPSIS-CAUSING MICROBIAL 
AGENTS RANGING FROM GRAM-NEGATIVE  
BACTERIA TO EBOLA VIRUS 
Gram-negative bacteria produce LPS, known as “endotoxin,” 
that is a very potent proinflammatory virulence factor inducing 
genomic storm in humans and experimental animals (see be-
low) [51]. Rickettsiae, which cause epidemic typhus and Rocky 
Mountain spotted fever (RMSF), demonstrate astonishingly 
effective entry and spread within microvascular endothelium 
to produce signs of rapidly evolving septic shock. The RMSF 
microbial agent, Rickettsia ricketsii, transmitted by an infected 
tick, is a frequent offender in the southeastern United States. It 
causes fever, headaches, myalgias and petechial rash in 85% 
of patients [55]. Relevant to the scope of this review, it may 
cause myocarditis manifested by chest pain, elevated cardiac 
enzyme levels, and myocardial dysfunction mimicking coro-
nary heart disease [56]. A prospective study of vaccinated and 
unvaccinated volunteers infected with Rickettsia ricketsii and 
promptly treated with antimicrobial therapy has demonstrated 
laboratory evidence of microvascular endothelial activation 
and injury [57]. 
More dramatic microvascular endothelial injury with 
florid bleeding diathesis is noted in patients infected with 
Ebola virus during recent epidemic outbreaks in Africa [58]. 
Rapidly spreading Ebola virus employs a virion glycoprotein 
that preferentially binds to endothelial cells, causing their 
death within 12 to 16 h [29]. Once inside the endothelial 
cells, the virus deploys VP24 protein to disarm the host in-
nate immune response mediated by interferons. Moreover, 




a defensive decoy made of truncated virion glycoprotein [59, 
60]. Of note, a patient’s genomic signature encoding HLA 
proteins determines whether the infected patient survives or 
dies from sepsis caused by the Sudan species of Ebola virus 
[61]. HLA represents the most polymorphic region in hu-
man genome that includes the human leukocyte antigen-B 
locus. Thus, alleles B*67 and B*15 were associated with fatal 
outcome whereas B*07 and B*14 hailed survival, indicating 
that these alleles control host response to Ebola virus and 
the outcome of sepsis. These lessons from Ebola virus sepsis 
call for a similar genomic analysis of human sepsis due to 
other microbial agents to predict more precisely its course 
and outcome. 
GRAM-NEGATIVE BACTERIA DOMINATE  
THE SEPSIS BATTLEFIELD 
Two-thirds of patients with sepsis are infected with 
Gram-negative bacteria either alone or together with 
other microbial agents [62]. Sepsis-causing bacteria rapidly 
propagate before effective, pathogen-directed anti-microbial 
therapy is initiated. They reach a quorum (stationary phase) 
during which their genes encoding virulence factors are 
activated and their products released [63]. LPS (also known 
as endotoxin), an integral component of the outer mem-
brane of Gram-negative bacteria, is highly diverse. Different 
strains of Gram-negative bacteria display structurally-distinct 
LPS including its toxic component lipid A [64]. Hence, the 
biologic activity of LPS differs, as exemplified by Escherichia 
coli and Neisseria meningitides [65]. Analysis of systemic 
inflammation induced by LPS derived from a single bacterial 
species provides valuable information about the mechanism 
of action of that particular LPS. However, a polymicrobial 
sepsis model, which is based on intraperitoneal injection 
of gut microbiome (“cecal slurry”), infects the host with 
a multitude of Gram-negative bacteria expressing diverse 
LPS structures and additional virulence factors as well as 
Gram-positive bacteria and other microbes [39, 66]. In this 
clinically-relevant model, the host’s defenses are multiply 
challenged by diverse bacteria thereby raising the bar for 
testing new and more effective countermeasures. 
Sepsis-causing microbial agents are aided by the host-pro-
duced inflammatory mediators in damaging microvascular 
endothelium [4]. These “co-conspirators” include comple-
ment factors, cytokines, chemokines, adhesion molecules, 
inducible COX-2 and NOS metabolites. In addition, damaged 
cells release their constituents’ termed host endogenous 
products, e.g. haemoglobin [67, 68] that add insult to initial 
injury exerted upon microvascular endothelial cells. Hence 
“anoikis,” apoptosis of endothelial cells detached from ex-
tracellular matrix, ensues. These detached and “homeless” 
endothelial cells circulate in blood and can be detected, 
counted and characterised, including increasingly available 
genomic analysis [69]. 
SPEEDY IDENTIFICATION AND TREATMENT  
OF SEPSIS-CAUSING MICROBES TO AVERT  
A FULL BLOWN GENOMIC STORM
Traditional and lengthy methods of microbiologic diagnosis 
based on culture and identification of suspected microbial 
agents are being gradually replaced by novel methods of 
microbial detection. In addition to the real-time polymerase 
chain reaction-based techniques, new methods of fluorescent 
in situ hybridisation, matrix-assisted laser desorption/ionisa-
tion-time-of-flight mass spectrometry are speeding up turna-
round time to about 30 to 150 min for staphylococci and 
their anti-bacterial resistance elements [70]. These diagnostic 
advances allow early administration of the specific patho-
gen-directed anti-microbial therapy during the first “golden 
hour,” including patient’s prehospital settings. Of course, the 
ultimate goal is to gain an early hold on invading microbial 
agent to avert wide-spread microvascular changes in patients 
suspected of harbouring sepsis-causing infections. While bac-
teria are being eliminated, their virulence factors (e.g. LPS, 
staphylococcal and streptococcal toxins, anthrax toxins) may 
not desist after initiation of pathogen-directed anti-microbial 
therapy. These virulence factors can remain in microcirculation 
and continue to inflict damage to blood cells and microvas-
cular endothelial cells unless the host’s innate and adaptive 
immune systems execute a rapid clearance of microbial agents 
and their toxic virulence factors [41, 71]. 
GENOMIC STORM IS CAUSED BY MICROBIAL  
VIRULENCE FACTORS THAT RAPIDLY  
REPROGRAMME HUMAN GENOME 
When their growth remains unrestrained, especially in 
extravascular loci less readily penetrated by anti-microbial 
agents, bacteria reprogram their genomes through a quorum 
sensing mechanism and produce multiple virulence factors 
that potentiate microvascular injury [63, 72, 73]. As depicted 
in Figure 3, bacterial and fungal virulence factors and viral 
nucleic acids initiate the host’s innate immune response. Its 
mainstays are the pattern recognition receptors, e.g. toll-like 
receptors (TLRs), present in immune cells and non-immune 
endothelial and epithelial cells [74, 75]. TLR4 is a canonical 
receptor for LPS, a virulence factor known as the most active 
biologic inducer of systemic inflammation [76]. 
Toll-like receptors initiate signalling cascades to the 
nucleus upon binding of microbial virulence factors and other 
products. These cascades activate SRTFs, such as NF-kB, AP-1, 
NFAT, and STAT-1a (Fig. 3) [77]. Each of them, either alone 
or in combination, activates multiple genes that encode pro-
inflammatory cytokines and chemokines, as well as their re-
ceptors, signal transducers, and cell adhesion molecules. This 
“across the board” activation of hundreds of genes in humans 
and experimental animals is termed a genomic storm [51, 78]. 
The products of multiple genes activated during genomic 




responsible for low blood pressure, microvascular endothe-
lial injury that underlies acute respiratory distress syndrome, 
disseminated intravascular coagulation, and multiple organ 
dysfunction, culminating in potentially lethal vascular collapse 
refractory to vasopressors and fluid resuscitation, a condition 
known as septic shock [2, 79]. Thus, signalling to the host 
cell’s nucleus constitutes a fundamental process of microbial 
inflammation evolving from innate immunity [77].
GENOMIC STORM IN EXPERIMENTAL  
POLYMICROBIAL SEPSIS CAN BE EXTINGUISHED 
BY TARGETING NUCLEAR TRANSPORT OF SRTF
Sepsis non-survivors displayed strikingly increased levels of 
a key SRTF, NF-kB, in nuclei of peripheral blood mononuclear 
cells [80]. In agreement with this hallmark of human sepsis, we 
found not only increased nuclear content of NF-kB1 (p50) and 
NF-kB RelA (p65) but also phosphorylated STAT-1a (MW91), 
Figure 3. Nuclear transport is a pivotal checkpoint in genomic regulation of microbial inflammation. Inflammatory signalling 
cascades initiated by cell responses to microbial virulence factors and cytokines culminate in nuclear translocation of stress- 
-responsive transcription factors (SRTFs) that upregulate inflammatory gene networks. Unchecked, this genomic reprogramming 
(genomic storm) leads to endothelial dysfunction, multi-organ failure, and ultimately fatal shock. Inhibiting nuclear transport at 
a common “checkpoint” located downstream of toll-like receptors (TLRs) and cytokine receptors globally suppresses expression 
of inflammatory genes thereby calming the genomic storm and averting multiple organ injury; AP-1 — activator protein 1;  
Ca2+ — calcium ions; CaM — calmodulin; IFNGR — interferon-gamma receptor; IFN-g — interferon-gamma; IKK — I kappa B 
kinase; IL-1, IL-6, IL-10, and IL-17 — interleukin 1, 6, 10 and 17, respectively; IL-1R — interleukin 1 receptor; Imp a5 — importin 
alpha 5; Imp b1 — importin beta 1; IRAK — interleukin-1 receptor-associated kinase; IkBa — NF-kB inhibitor alpha; JAK —  
Janus kinase; JNK — c-Jun N-terminal kinase; MAPKs — mitogen-activated protein kinases; MCP-1 — monocyte chemoattractant 
protein-1; MyD88 — myeloid differentiation primary response 88; NFAT — nuclear factor of activated T cells; NF-kB — nuclear 
factor kappa B; NPC — nuclear pore complex; P — phosphate group; SFKs — Src family of protein tyrosine kinases; STAT1 —  
signal transducer and activator of transcription 1; TNFa — tumour necrosis factor alpha; TRAF6 — TNF receptor-associated factor 6; 




phosphorylated STAT1a (MW84) and AP-1 (cFos) in liver cells 
of septic animals comprising hepatocytes, macrophages, and 
microvascular endothelial cells, among other cells [39]. 
This multi-stage process of proinflammatory and meta-
bolic signalling to the cell’s nucleus can be interrupted by 
targeting nuclear transport, a pivotal checkpoint integrating 
translocation of multiple transcription factors to the nucleus 
(Fig. 3), Thus, instead of targeting one signalling cascade of 
individual transcription factor, it would be a more efficient 
strategy to inhibit in a one swipe several signalling cascades 
that converge at the nuclear import step. This concept was 
proven by design and development of NTMs [4, 51, 77, 81]. 
Nuclear transport modifiers have been shown to inhibit 
nuclear translocation of SRTFs, such as NF-kB, AP-1, NFAT, 
and STAT-1 [82], and sterol regulatory element binding 
proteins (SREBPs) [81] thereby impeding nuclear delivery of 
proinflammatory and metabolic transcription factors. NTMs 
displace nuclear import cargo from its binding pocket on 
importin a5 and importin b1, that translocate SRTFs and meta-
bolic transcription factors SREBPs to the nucleus. Thereby, 
signal transduction pathways, which culminate in genomic 
reprogramming, can be controlled [51, 81]. Importin b1 is 
a sole transporter of SREBPs to the nucleus [81]. NTM’s signal 
sequence hydrophobic region (SSHR) that inhibits binding of 
SREBPs to importin b1 also serves as a membrane translocating 
motif to enable intracellular delivery of peptides and proteins 
through an ATP- and endocytosis-independent mechanism 
[83]. Consequently, proinflammatory reprogramming of the 
genome is prevented in multiple cells that slow down producing 
inflammatory, procoagulant, proapoptotic, and autoimmune 
mediators. Hence, inflammatory responses, microvascular in-
jury, apoptosis and haemorrhagic necrosis are suppressed with 
a concomitant gain in survival, in models of lethal shock induced 
by bacterial toxins [34, 84–86]. Strikingly, NTM reduced plasma 
levels of 23 out of 26 LPS-induced proinflammatory cytokines, 
chemokines, and growth factors thereby calming the genomic 
storm [51]. Some of these NTM-suppressed cytokines (TNF-a, 
IL-1, IL-6, and IL-17) are targeted solo by expensive monoclonal 
antibody therapy. 
In an experimental model of polymicrobial sepsis, simul-
taneous targeting of nuclear transport adaptors importin a5 
and importin b1 with NTM not only attenuated nuclear import 
of SRTFs and maintained metabolically-important glycogen 
stores in the liver but significantly reduced bacterial burden in 
blood, spleen, and lungs. The clearance of bacteria in the lung 
was increased 700-fold prior to the initiation of anti-microbial 
therapy (Fig. 4). Moreover, NTM attenuated proinflammatory 
cytokines and chemokines in blood, preserved normal platelet 
count in blood, and reduced plasma markers of microvascular 
injury (Fig. 4) as well as neutrophil infiltration of the liver [39]. 
These apparent cytoprotective effects of NTM contributed to 
a significant gain in survival from 30% on antibiotic therapy 
alone to 55% on combination of NTM with antibiotic (Fig. 5). 
METABOLIC DERANGEMENTS IN SEPSIS 
The impact of sepsis on human body metabolism has been 
analysed in a large cohort of patients with suspected, commu-
nity-acquired sepsis [12]. The great majority of patients with 
sepsis caused by Streptococcus pneumoniae, Staphylococcus 
aureus, and Escherichia coli survived, with a 28-day mortal-
ity of 4.9%. Non-survivors and survivors consistently showed 
divergent values in several metabolic parameters studied. 
First, as predicted, lactate, an established marker of sepsis 
severity, was elevated in sepsis non-survivors group. Second, 
alterations in fatty acid metabolism produced a prominently 
different metabolomic phenotype of sepsis survival and 
death. Six plasma carnitine esters were decreased in sepsis 
survivors. In contrast, 16 carnitine esters and four fatty acids 
were elevated in sepsis non-survivors as compared to con-
trols. In agreement with a previous study [87], this analysis 
points to a consistent defect in b-fatty acid oxidation in sepsis 
non-survivors attributed to a malfunctioning mitochondrial 
shuttle for acyl carnitines. Their excess in plasma may cause 
ventricular diastolic dysfunction of the heart [88]. The plasma 
proteome analysis established that 22 complement compo-
nents were elevated in sepsis non-survivors along with nine 
fatty acid transport proteins. As fatty acid metabolism, along 
with that of triglycerides and cholesterol, is transcriptionally 
regulated by SREBPs, their role in sepsis-induced metabolic 
dysregulation awaits further studies (see above). 
Recently, McGarrity et al. [13] reported metabolic system 
analysis of LPS-induced endothelial dysfunction and its poten-
tial application to the stratification of patients with sepsis. They 
built Genome Scale Metabolic Model (GEM) for resting and 
activated human endothelium and found that patient plasma 
from non-survivors displays increased glycan metabolism. 
SEPSIS AT THE EXTREMES OF AGE 
Among all age groups, infants and elderly are most suscepti-
ble to sepsis and its fatal outcome. Among infants, neonatal 
sepsis survivors are prone to development of life-long disabili-
ties. As the newborn immune system is immature, including 
dysregulated physiologic anti-inflammatory suppressors [89], 
the susceptibility to uncontrolled activation of inflammatory 
cascades is heightened. Uninfected prematurely born infants, 
who display the highest levels of IL-18 exceeding those in 
healthy adults, are particularly susceptible to sepsis [90]. 
IL-18 in adults is associated with hypotension, acute lung inju-
ry, and lethal shock. We established a novel axis that comprises 
IL-18/IL-1R1/IL-17A and underlies neonatal sepsis. Accordingly, 
genetic or pharmacologic targeting of IL-17 signalling pathway 
prevented the enhancement of experimental neonatal sepsis 
mortality in a relevant experimental model [90]. As monoclo-
nal antibody targeting IL-17 is available, this new advance in 
neonatal sepsis opens up a potential method of treatment.
At the other end of the age spectrum, incidence and 




65 years of age [79]. Advanced age-related immune decline is 
likely to combine with physiologic ageing in which defective 
nuclear lamin processing is associated with nucleoplasmic 
lamin A/C and vascular ageing in the normal population [91]. 
Increased susceptibility to sepsis is also observed in acceler-
ated ageing (Hutchison-Gilford progeria) [92]. Accelerated 
ageing is caused by mutations in nuclear lamins. Laminopa-
thies are linked to transcriptional dysregulation, oxidative 
stress, inflammatory signalling, vascular smooth muscle 
apoptosis, and accelerated atherosclerosis [93]. We found 
that innate immunity adaptor SARM protects lamins from 
inflammation-induced apoptotic degradation [94]. 
Moderate-to-severe cognitive impairment was discovered 
in a large cohort of sepsis survivors as compared to non-sepsis 
patients [95]. Sepsis survivors encompass not only elderly 
patients who suffer from rapidly progressing cognitive de-
cline. More recent prospective study of employment among 
the younger survivors of critical illness (cardiogenic or septic 
shock) revealed that approximately half was unemployed 
after their illness [96]. Moreover, impaired cognitive func-
tion at 12 months after hospital discharge was a predictor of 
subsequent employment status. 
These troubling outcomes of sepsis and other critical 
illnesses have profound consequences for patients, their 
families, and societal resources for long-term care. Hence, 
they add immeasurably to the high human and economic 
cost of sepsis that exceeded $20 billion in the United States 
in 2011 [97]. 
Figure 4. Improvement of bacterial clearance and biomarkers of endothelial injury in infected mice treated with nuclear transport 
modifier (NTM) (cSN50.1 peptide). A. Colony-forming units (CFU) determined by serial dilution of whole blood and organ homo-
genates collected 12 h after infection from sham- or gut microbiome-containing cecal slurry (CS)-infected mice treated with NTM 
(cSN50.1 peptide) or vehicle. Bars represent median values from four to five mice/group (p values determined by Mann-Whitney 
test); B. Endothelial and leucocyte biomarkers, namely, soluble E-selectin, L-selectin, and P-selectin measured in blood plasma 
before and at 12 h and 24 h after CS infection. Antibiotic therapy with meropenem began at 12 h post-infection (p values for  
sE-selectin and sL-selectin calculated by two-way repeated measures ANOVA, p value for sP-selectin determined by Mann-Whitney 
test at 24 h only, n = 9/group) (adapted from [39]); *p < 0.05 only at 24 h. The vertical line represents the standard error of the 






IMMUNOPROPHYLAXIS OF SEPSIS 
Vaccines against microbial agents that cause sepsis signifi-
cantly impact the incidence of sepsis-causing infections. The 
incidence of pneumococcal sepsis due to infection with 
Streptococcus pneumoniae has been greatly reduced. The 
potentially fatal complications in patients with pneumonia, 
and those born with asplenia, sickle cell anaemia, and under-
going splenectomy are prevented. Strikingly, administration of 
pneumococcal vaccine to children reduced dramatically child-
hood pneumococcal sepsis but also adult sepsis [98]. Remark-
ably, non-vaccinated older adults, including the 65–74- and 
75–84-year-old age groups, displayed a significant reduction 
in hospitalisation for pneumonia and its invasive complication, 
sepsis. This important example of “herd immunity” teaches 
us that consistent vaccination of children, as the main carri-
ers of targeted microbial agent (Streptococcus pneumoniae), 
reduces its transmission to parents, grandparents, and other 
adults in contact with children. Presently this vaccination has 
been extended to older age groups as well. 
Likewise, a vaccine against group B Neisseria meningitides 
reduced the incidence of meningococcal sepsis among college 
students and military recruits. Rarely, a patient with purpura 
fulminans is now being encountered in paediatric and adult 
emergency rooms. Patients with deficiency of blood comple-
ment membrane attack complex are particularly prone to 
meningococcal or gonococcal sepsis. While antibiotic therapy 
is effective in limiting rapidly progressing microvascular injury, 
young patients with meningococcal sepsis suffer not only from 
hearing loss and neurological damage but also lose their limbs 
due to amputations [99]. Similarly, patients with the inborn 
defects of innate immunity (IRAK-4 and MyD88 deficien-
cies detected through genomic diagnosis of children with 
recurrent infections) should be immunised with S. pneumo-
niae conjugated and nonconjugated vaccines, Haemophilus 
influenzae conjugated vaccine, and Neisseria meningitides 
conjugated and nonconjugated vaccines [100]. Clearly, im-
munoprophylaxis is the most rational and beneficial method 
of sepsis prevention. 
FUTURE OUTLOOK 
While working among colleagues who take care of patients 
with sepsis, I share their frustration with a continuing lack of 
new cytoprotective drugs approved for treatment of sepsis 
and its sequelae. Likewise, there is a woefully slow pace of 
development of new antimicrobials. Advances in immuno-
prophylaxis such as Ebola virus vaccine are also slow to come. 
The heart-wrenching consequences of sepsis in neonates who 
survive and suffer from developmental disabilities and in the 
middle-aged or elderly survivors, who experience a cognitive 
decline adversely affecting their prospect for employment and 
independent living, evoke a call to action. 
All of us benefit directly or indirectly (“a herd immunity”) 
from the pneumococcal vaccine. Younger individuals are also 
protected by meningococcal vaccine when they enter college 
or military service. Hence, they (and their parents) no longer 
fear purpura fulminans. However, immunoprophylaxis for 
other sepsis-causing Gram-negative bacteria and staphylo-
cocci is lagging behind. It is partly due to a huge diversity 
of Gram-negative bacteria and the pervasive make-up of 
staphylococci. Luckily, steady progress with anti-microbial 
monoclonal antibodies bodes well for this form of immuno-
prophylaxis or immunotherapy. Ideally, ultra-rapid identifica-
tion of sepsis-causing microbial agents should be met with 
the development of a panel of therapeutic cross-reactive 
monoclonal antibodies crafted for a group of related patho-
gens. A patient’s genome susceptibility loci identified by 
whole genome sequencing should be available with proper 
privacy guidelines from his/her electronic health record to 
map the optimal preventive and therapeutic strategies. In 
parallel, comprehensive countermeasures for sepsis-mediating 
genomic storm are emerging as therapeutic companion to 
antimicrobials and anti-microbial monoclonal antibodies. 
Getting there in a heartbeat should be “a dream with the 
deadline” for all involved. 
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